Summit Trail Advisors LLC Cuts Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Summit Trail Advisors LLC lessened its position in DexCom, Inc. (NASDAQ:DXCM) by 15.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,441 shares of the medical device company’s stock after selling 461 shares during the quarter. Summit Trail Advisors LLC’s holdings in DexCom were worth $303,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in DXCM. Vestmark Advisory Solutions Inc. boosted its stake in DexCom by 555.0% during the fourth quarter. Vestmark Advisory Solutions Inc. now owns 36,044 shares of the medical device company’s stock worth $4,473,000 after buying an additional 30,541 shares during the last quarter. Axxcess Wealth Management LLC purchased a new stake in shares of DexCom in the fourth quarter valued at about $208,000. 9258 Wealth Management LLC acquired a new stake in DexCom during the fourth quarter worth about $286,000. Natixis Advisors L.P. raised its stake in DexCom by 141.4% during the fourth quarter. Natixis Advisors L.P. now owns 1,129,570 shares of the medical device company’s stock worth $140,168,000 after purchasing an additional 661,584 shares during the period. Finally, First Trust Direct Indexing L.P. increased its holdings in shares of DexCom by 16.7% during the 4th quarter. First Trust Direct Indexing L.P. now owns 9,920 shares of the medical device company’s stock worth $1,231,000 after buying an additional 1,418 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently weighed in on DXCM. UBS Group increased their price objective on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Canaccord Genuity Group increased their price target on DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a report on Friday, April 26th. Citigroup boosted their price objective on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Royal Bank of Canada began coverage on shares of DexCom in a research note on Tuesday, March 12th. They set an “outperform” rating and a $165.00 target price for the company. Finally, Raymond James lifted their price target on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research report on Friday, April 26th. Three equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and a consensus price target of $141.67.

Insider Transactions at DexCom

In other news, CEO Kevin R. Sayer sold 81,007 shares of DexCom stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the completion of the sale, the chief executive officer now directly owns 333,526 shares of the company’s stock, valued at approximately $44,479,027.36. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, EVP Michael Jon Brown sold 629 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $126.25, for a total transaction of $79,411.25. Following the completion of the sale, the executive vice president now owns 68,212 shares in the company, valued at approximately $8,611,765. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kevin R. Sayer sold 81,007 shares of the stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the completion of the transaction, the chief executive officer now directly owns 333,526 shares in the company, valued at $44,479,027.36. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 190,004 shares of company stock valued at $25,610,270. 0.41% of the stock is currently owned by corporate insiders.

DexCom Stock Performance

NASDAQ:DXCM opened at $127.42 on Thursday. DexCom, Inc. has a 52 week low of $74.75 and a 52 week high of $142.00. The company has a fifty day simple moving average of $132.94 and a two-hundred day simple moving average of $121.16. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08. The company has a market cap of $50.67 billion, a price-to-earnings ratio of 82.21, a price-to-earnings-growth ratio of 2.19 and a beta of 1.23.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The firm had revenue of $921.00 million during the quarter, compared to analyst estimates of $911.20 million. As a group, equities analysts anticipate that DexCom, Inc. will post 1.78 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.